Bleakley Financial Group LLC Acquires Shares of 5,376 Harrow, Inc. (NASDAQ:HROW)

Bleakley Financial Group LLC acquired a new stake in Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,376 shares of the company’s stock, valued at approximately $242,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in Harrow during the 2nd quarter worth about $33,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after buying an additional 2,048 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Harrow by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock worth $248,000 after buying an additional 567 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Harrow during the third quarter worth about $534,000. Finally, Bayesian Capital Management LP purchased a new position in Harrow during the first quarter valued at approximately $185,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Down 4.8 %

HROW stock opened at $54.22 on Thursday. Harrow, Inc. has a 52 week low of $7.60 and a 52 week high of $59.23. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18. The firm has a 50-day simple moving average of $45.41 and a 200-day simple moving average of $28.13. The stock has a market capitalization of $1.92 billion, a P/E ratio of -59.58 and a beta of 0.75.

Harrow (NASDAQ:HROW) last announced its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. The business had revenue of $48.94 million during the quarter, compared to analysts’ expectations of $42.78 million. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. Equities analysts forecast that Harrow, Inc. will post -0.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Lake Street Capital lifted their target price on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th. Craig Hallum upped their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley restated a “buy” rating and set a $50.00 target price on shares of Harrow in a research report on Thursday, August 29th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.